Author

M. Gonen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Acilan· 2 shared E. De Stanchina· 2 shared R. Koche· 2 shared A. Blackford· 1 shared A. C. Aksu· 1 shared A. Cingoz· 1 shared A. Eisenberg· 1 shared A. Gazzo· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Acilan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Less is More: Nek2A Unclusters Extra Centrosomes and Induces Cell Death in Cancer Cells via KIF2C Interaction

B. M. Kalkan, S. C. Ozcan, E. Cicek, M. Gonen, C. Acilan

This study shows Nek2A unclusters extra centrosomes and induces cell death in cancer cells, but not in normal cells, through interaction with KIF2C.

bioRxiv · Nov 21, 2023Cancer Biology

Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity

M. N. Brodeur, H. Dopeso, Y. Zhu, A. L. F. Longhini, A. Gazzo, S. Sun, R. Koche, R. Qu, P.-J. Hamard, Y. Bykov, H. Green, K. B. Chiappinelli, M. A. Ozsoy, T. Basili, R. Gardner, , D. Zamarin

This study shows that SMARCA4 mutations in ovarian cancer increase immunogenicity through interferon response and epigenetic changes, enhancing T cell and NK cell activity in the tumor microenvironment.

bioRxiv · Aug 8, 2023 · PreprintCancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors

A. Henssen, R. Koche, J. Zhuang, E. Jiang, C. Reed, A. Eisenberg, E. Still, I. MacArthur, E. Rodriguez-Fos, S. Gonzalez, M. Puiggros, A. Blackford, C. Mason, E. De Stanchina, M. Gonen, , A. Kentsis

This study identifies PGBD5 as an oncogenic DNA transposase in rhabdoid tumors, causing site-specific genomic rearrangements through PSS sequences and end-joining repair.

bioRxiv · Feb 23, 2017Cancer Biology